

ASX Announcement (ASX: HLS)

ASX Limited
Market Announcements Office
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000

8 December 2025



ACN 064 530 516
REGISTERED OFFICE:
LEVEL 22
161 Castlereagh Street
SYDNEY NSW 2000
TEL: +61 2 9432 9400
FAX: +61 2 9432 9447

Board Changes

Healius Limited ("**Healius**") (ASX: HLS) announces the appointment of a new independent Non-Executive Director, Professor Bruce Robinson AC, and the retirement of Non-Executive Director Professor John Mattick AO.

Professor Robinson's appointment to the Board will be effective from 2 February 2026 and Professor Mattick will retire on 31 March 2026.

Professor Robinson is a renowned physician, academic, and advisor with over 25 years' experience as a leader in healthcare. In addition to being a highly experienced practising endocrinologist, Professor Robinson currently serves as a Non-Executive Director of major listed healthcare entities Cochlear Limited (ASX:COH) (since 13 December 2016) and Mayne Pharma Group Limited (ASX:MYX) (since 26 August 2014). He is also a Non-Executive Director of British speciality pharmaceutical company CS Pharmaceuticals Ltd (since 24 October 2024), a Senior Advisor to McKinsey & Company and an advisor to Minter Ellison.

Professor Robinson's former roles include Chair of the Australian Government's taskforce of expert clinicians charged with reviewing the Medicare Benefits Schedule, the Medical Benefits Schedule Review Taskforce, and chair of Australia's peak advisory and funding body for medical research, the National Health and Medical Research Council. He is a former Dean of the University of Sydney's Medical School, the former head of the Cancer Genetics Unit at the Kolling Institute, Royal North Shore Hospital, and the former Head, Division of Medicine, Royal North Shore Hospital.

Professor Robinson was awarded a Doctor of Medicine from the University of Sydney in 1990, having earlier undertaken a fellowship at Harvard Medical School and graduated from the University of Sydney with a Master of Science degree. Professor Robinson is a Fellow of the Australian Institute of Company Directors.

Professor Mattick was appointed to the Board as a Non-Executive Director in March 2022 and has served as a member of the Board's Audit Committee and Risk Management Committee.

Kate McKenzie, Healius Chair, said: "The Board is honoured to be joined by Professor Robinson. Bruce's extensive experience as a medical professional and leader across public and private health providers will be an important addition to the Board's collective skillset.

At the same time as welcoming Bruce, the Board thanks Professor Mattick for his valuable insights throughout his tenure with Healius. John's expertise in the use of genetic information in healthcare has been particularly valuable during strategy development for our Genomics Diagnostic business. We wish John well in his retirement."

ENDS

The release of this announcement has been authorised by the Chair of Healius.

For further information contact:

Kate McKenzie

Chair

Healius Limited

+61 (0) 466 023 858

investor.relations@healius.com.au